References
- Secker-Walker L M, Moorman A V, Bain B J, Mehta A B, on behalf of the European 11q23 Workshop participants. Secondary acute leukemia and myelodysplastic syndrome with 11q23 abnormalities. Leukemia 1998; 12: 840–844
- Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3066–3071
- Curtis R, Boice J, Stovall M, Bernstein L, Greenberg R, Flannery J, et al. Risk of leukaemia after chemotherapy and radiation treatment for breast cancer. New Engl J Med 1992; 326: 1745–1751
- Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003; 102: 2395–2402